论文部分内容阅读
为了提高化疗药物的治疗指数和降低其毒性，制备成柔红霉素－人血清白蛋白微球（Ｄａｕ－ＨＡ－ＭＳ）。绝大多数为单分散相微球，平均直径５６±１６μｍ，范围为２９～１９４μｍ，适用于导管动脉栓塞（ＴＡＥ）治疗。Ｄａｕ－ＨＡ－ＭＳ在生理盐水中能有效的释放Ｄａｕ，但无爆发释放的缺点。释放Ｄａｕ的光谱特性和体外细胞毒效应与原药相比无变化，表明Ｄａｕ通过微球制备仍保留原有的理化及生物学特性。实验表明，经腹腔注射Ｄａｕ－ＨＡ－ＭＳ使３０％的Ｓ－１８０腹水癌小鼠活存超过６个月，而肿瘤对照组及Ｄａｕ治疗组均分别在２１天和１４天全部死亡，说明Ｃａｕ－ＨＡ－ＭＳ有较好的疗效及较低的毒性。本结果提示，Ｄａｕ－ＨＡ－ＭＳ有可能用于人肝癌的ＴＡＥ治疗。
In order to increase the therapeutic index and reduce the toxicity of chemotherapeutic drugs, daunorubicin-human serum albumin microspheres (Dau-HA-MS) were prepared. The vast majority of monodisperse phase microspheres, the average diameter of 56 ± 16μm, the range of 29 ~ 194μm, suitable for catheter arterial embolization (TAE) treatment. Dau-HA-MS can effectively release Dau in normal saline, but has no disadvantage of burst release. The spectral characteristics and in vitro cytotoxicity of released Dau showed no change compared with the original drug, indicating that Dau still retains its original physicochemical and biological properties through microsphere preparation. Experiments showed that 30% of S-180 ascites carcinoma mice lived for more than 6 months after intraperitoneal injection of Dau-HA-MS, while tumor control group and Dau treatment group all died at 21 days and 14 days respectively, indicating that Cau - HA-MS has better efficacy and lower toxicity. This result suggests that Dau-HA-MS may be used for TAE treatment of human liver cancer.